SPOTLIGHT: Fledgling biotech hunts for cash


The backers of a fledgling northern Virginia biotech named Cary Pharmaceuticals has been out beating the bushes for $14 million in new investment funds to carry the company into the clinic. So far, about $2.6 million has been raised from family, friends, a federal grant and a manufacturing partner. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.